Revelation Biosciences warns of delisting risk; stockholders' equity only $1.14M vs $2.5M minimum

REVELATION BIOSCIENCES, INC.

Received Nasdaq letter on Aug 14, 2024, citing insufficient stockholders' equity of $1,140,421 vs required $2.5M.
Also failed alternative listing standards (market value of listed securities ≥$35M or net income from continuing ops $500K).
Company has 45 days to submit a plan to regain compliance; Nasdaq may grant up to 180-day extension.
No immediate effect on trading; common stock and warrants continue trading under REVB and REVBW.
Company intends to take reasonable measures but no assurance of extension or regaining compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.